Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
BMJ Health Care Inform ; 28(1)2021 May.
Article in English | MEDLINE | ID: mdl-34035050

ABSTRACT

BACKGROUND/AIMS: To assess the outcomes of home monitoring of distortion caused by macular diseases using a smartphone-based application (app), and to examine them with hospital-based assessments of visual acuity (VA), optical coherence tomography-derived central macular thickness (CMT) and the requirement of intravitreal injection therapy. DESIGN: Observational study with retrospective analysis of data. METHODS: Participants were trained in the correct use of the app (Alleye, Oculocare, Zurich, Switzerland) in person or by using video and telephone consultations. Automated threshold-based alerts were communicated based on a traffic light system. A 'threshold alarm' was defined as three consecutive 'red' scores, and turned into a 'persistent alarm' if present for greater than a 7-day period. Changes of VA and CMT, and the requirement for intravitreal therapy after an alarm were examined. RESULTS: 245 patients performing a total of 11 592 tests (mean 46.9 tests per user) were included and 85 eyes (164 alarms) examined. Mean drop in VA from baseline was -4.23 letters (95% CI: -6.24 to -2.22; p<0.001) and mean increase in CMT was 29.5 µm (95% CI: -0.08 to 59.13; p=0.051). Sixty-six eyes (78.5%) producing alarms either had a drop in VA, increase in CMT or both and 60.0% received an injection. Eyes with persistent alarms had a greater loss of VA, -4.79 letters (95% CI: -6.73 to -2.85; p<0.001) or greater increase in CMT, +87.8 µm (95% CI: 5.2 to 170.4; p=0.038). CONCLUSION: Smartphone-based self-tests for macular disease may serve as reliable indicators for the worsening of pathology and the need for treatment.


Subject(s)
Intravitreal Injections/statistics & numerical data , Macular Degeneration , Remote Consultation/statistics & numerical data , Smartphone , Visual Acuity/physiology , Aged , Female , Humans , Macular Degeneration/diagnosis , Macular Degeneration/pathology , Male , Mobile Applications , Retrospective Studies , Tomography, Optical Coherence
7.
Am J Ophthalmol ; 156(1): 50-52.e1, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23540710

ABSTRACT

PURPOSE: To investigate the spectrum of organisms causing culture-proven endophthalmitis and their susceptibilities to commonly used antimicrobial agents over 10 years. DESIGN: Retrospective, noncomparative, consecutive case series. METHODS: Medical records were reviewed of all cases with culture-proven endophthalmitis at a single institution from 2002 through 2011. The outcome measures included all intravitreal isolates identified as well as antibiotic susceptibilities. RESULTS: A total of 448 organisms were isolated during the study interval. The most common organisms identified were Staphylococcus epidermidis in 30.1% (135/448), Streptococcus viridians group in 10.9% (49/448), Staphylococcus aureus in 7.8% (35/448), Candida albicans in 5.8% (26/443), other coagulase-negative staphylococci in 6.0% (27/448), Propionibacterium acnes in 4.7% (21/448), and Pseudomonas aeruginosa in 3.1% (14/448). Overall, 327 (72.9%) of 448 isolates were gram-positive organisms, 48 (10.7%) of 448 isolates were gram-negative organisms, 71 (15.8%) of 448 isolates were fungi, and 2 (0.4%) of 448 isolates were viruses. For gram-positive organisms, susceptibilities were the following: vancomycin, 100%; gentamicin, 88.0%; sulfamethoxazole/trimethoprim, 77.5%; levofloxacin, 58.5%; oxacillin, 54.7%; ciprofloxacin, 51.0%; gatifloxacin, 51.0%; and moxifloxacin, 47.0%. For gram-negative organisms, susceptibilities were the following: ceftazidime, 100%; levofloxacin, 100%; ciprofloxacin, 95.0%; tobramycin, 90.6%; gentamicin, 80.6%; and sulfamethoxazole/trimethoprim, 59.4%. CONCLUSIONS: In the current study, no single antibiotic provided coverage for all of the microbes isolated from eyes with endophthalmitis. Combination therapy generally is the recommendation as the initial empiric treatment of suspected bacterial endophthalmitis. Appropriate history and characteristic clinical features may guide the use of initial antifungal agents.


Subject(s)
Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Endophthalmitis/microbiology , Eye Infections, Bacterial/microbiology , Eye Infections, Fungal/microbiology , Anti-Bacterial Agents/therapeutic use , Bacteria/isolation & purification , Endophthalmitis/drug therapy , Eye Infections, Bacterial/drug therapy , Eye Infections, Fungal/drug therapy , Fungi/drug effects , Fungi/isolation & purification , Humans , Microbial Sensitivity Tests , Retrospective Studies , Vitreous Body/microbiology
11.
Ophthalmic Surg Lasers Imaging ; 42 Suppl: S41-55, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21790110

ABSTRACT

Optical coherence tomography (OCT) is an important imaging modality in the setting of diabetic macular edema (DME). Its use allows more precise evaluation of retinal pathology in DME, including retinal thickness and edema, vitreomacular interface abnormalities, subretinal fluid, and foveal microstructural changes. Additional advantages include its ability to quantitatively monitor response to treatment of DME by laser, intravitreal pharmacotherapies, and vitreoretinal surgery. OCT measurements are now used in all major clinical studies of DME treatment as critical endpoints. This article presents a review of both time-domain and spectral-domain OCT in the diagnosis and management of DME. The authors discuss the various parameters evaluated by the OCT systems and provide an evidence-based evaluation of their accuracy, significance, reliability, and limitations. As the capability of OCT continues to advance, it appears that its use will play an increasingly important role in the understanding, evaluation, and treatment of DME.


Subject(s)
Diabetic Retinopathy/diagnosis , Diagnostic Techniques, Ophthalmological , Macular Edema/diagnosis , Tomography, Optical Coherence , Diabetic Retinopathy/therapy , Humans , Macular Edema/therapy
12.
Am J Pathol ; 178(5): 2032-43, 2011 May.
Article in English | MEDLINE | ID: mdl-21457933

ABSTRACT

Oxidative stress plays a critical role in accelerating retinal pigment epithelial dysfunction and death in degenerative retinal diseases, including age-related macular degeneration. Given the key role of oxidative stress-induced retinal pigment epithelial cell death and secondary photoreceptor loss in the pathogenesis of age-related macular degeneration, we hypothesized that a novel thiol antioxidant, N-acetylcysteine amide (NACA), might ameliorate cellular damage and subsequent loss of vision. Treatment of human retinal pigment epithelial cells with NACA protected against oxidative stress-induced cellular injury and death. NACA acted mechanistically by scavenging existing reactive oxygen species while halting production of reactive oxygen species by reversing lipid peroxidation. Furthermore, NACA functioned by increasing the levels of reduced glutathione and the phase II detoxification enzyme glutathione peroxidase. Treatment of mice exposed to phototoxic doses of light with NACA maintained retinal pigment epithelial cell integrity and prevented outer nuclear layer cell death as examined by histopathologic methods and rescued photoreceptor function as measured by electroretinography. These observations indicate that NACA protects against oxidative stress-induced retinal pigment epithelial and photoreceptor cell death in vitro and in vivo. The data suggest that NACA may be a novel treatment in rescuing retinal function and preventing vision loss secondary to retinal degenerative diseases, including age-related macular degeneration.


Subject(s)
Acetylcysteine/analogs & derivatives , Antioxidants/pharmacology , Glutathione/biosynthesis , Lipid Peroxidation/drug effects , Retinal Degeneration/prevention & control , Retinal Pigment Epithelium/drug effects , Acetylcysteine/pharmacology , Animals , Cells, Cultured , Free Radical Scavengers/pharmacology , Humans , Mice , Oxidative Stress/drug effects , Retinal Degeneration/metabolism , Retinal Pigment Epithelium/metabolism
13.
Ophthalmic Genet ; 27(1): 9-14, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16543196

ABSTRACT

PURPOSE: To describe the association between retinal degeneration and cobalamin C (cblC) disease and to review previously published ophthalmic data regarding cblC disease. METHODS: Descriptive case series of three patients and compilation of all previously reported cases of cblC disease in the ophthalmic literature. RESULTS: All three new cases presented with macular pigmentary changes and showed attenuation of electroretinographic responses. Sequential ERG (electroretinogram) testing in Case 1 demonstrated ERGs that began at the lower limits of normal and became progressively attenuated over time. CONCLUSIONS: Cobalamin C disease results in progressive retinal degeneration with its onset in the first few months of life and progressing rapidly over the first few years of life.


Subject(s)
Retinal Degeneration/etiology , Vitamin B 12 Deficiency/complications , Electroretinography , Female , Humans , Infant, Newborn , Retina/physiopathology , Retinal Degeneration/physiopathology , Vitamin B 12/therapeutic use , Vitamin B 12 Deficiency/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...